Eric Wang, Ph.D.

Eric Wang's Research Focus

Cancer, Immune Disorders, Molecular Biology
Adaptive Immunity, Cancer Biology, Disease Therapies, Tumor Microenvironment, Cell Biology
Chemical Biology, Drug Discovery

Dysregulation of transcriptional circuits is a common hallmark of disease, and in particular is found in both tumor and host immune cells in cancer. Eric’s lab is focusing on developing and using chemical tools to modulate the activity of key transcriptional regulators of both tumor cells and host immune cells, with a long-term goal of identifying new therapeutic approaches.

Eric Wang's Bio

Eric has a broad background in chemical biology, with specific training and expertise in kinase inhibitors and targeted protein degradation, an emerging modality in which small molecules recruit E3 ligase complexes to target proteins to induce their ubiquitination and subsequent proteasomal degradation. He also has experience in pharmacological modulation of immune cells to improve anti-tumor immunity.
 
He received his Ph.D. from the University of California San Francisco and postdoctoral training at the Dana-Farber Cancer Institute.

 

Education and Training

  • Postdoctoral Fellow, Dana-Farber Cancer Institute / Harvard Medical School, 2021
  • Ph.D., University of California San Francisco, 2015 B.S., Duke University, 2009

Fellowship

  • Damon Runyon Cancer Research Foundation Fellowship

general accessory

Publications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK

Cancer Discov 2018 Feb ;8(2):216-233

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS

Blood 2019 Feb 28 ;133(9):952-961

Acute pharmacological degradation of Helios destabilizes regulatory T cells.

Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES

Nat Chem Biol 2021 Jun ;17(6):711-717

Show All Select Publications

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, Litzow MR, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B

Blood Cancer J 2021 Oct 30 ;11(10):175

Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.

Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M

Lancet Haematol 2021 Oct 20 ;

Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.

King AC, Weis TM, Derkach A, Ball S, Pandey M, Mauro MJ, Goldberg AD, Stahl M, Famulare C, Tallman MS, Wang ES, Kuykendall AT, Rampal RK

Am J Hematol 2021 Oct 21 ;

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring W, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey EH

Blood 2021 Aug 5 ;138(5):387-400

Efficient Protoplast Regeneration Protocol and CRISPR/Cas9-Mediated Editing of Glucosinolate Transporter (GTR) Genes in Rapeseed (Brassica napus L.).

Li X, Sandgrind S, Moss O, Guan R, Ivarson E, Wang ES, Kanagarajan S, Zhu LH

Front Plant Sci 2021 ;12:680859

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R

Haematologica 2021 Jul 15 ;

Show All Publications